← 返回

抗原经历史决定抗白血病应答中 CD8⁺ CAR-T 细胞的不同功能状态

英文原题:Antigen experience history directs distinct functional states of CD8(+) CAR T cells during the antileukemia response.

查看英文原题

Antigen experience history directs distinct functional states of CD8(+) CAR T cells during the antileukemia response.

PubMed 2025/01/02(内容时间) Nat Immunol Q1 · IF 26.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

尽管嵌合抗原受体(CAR)T细胞可有效治疗B细胞系恶性肿瘤,CAR治疗后复发仍很常见,且其对其他肿瘤的疗效有限。通过合理调控CAR-T 细胞功能,或可应对这些挑战。本研究考察T细胞既往经历同源抗原后,对其后续CD8⁺ CAR-T 细胞活性的影响。既往抗原接触可增强CAR-T 细胞对靶抗原密度低的白血病的效应功能,但代价是增殖能力下降,且在CAR剂量受限时更易发生功能障碍。对初始细胞来源和记忆细胞来源CAR-T 细胞的不同时间点转录组及表观遗传特征分析,发现RUNX家族转录因子可能是增强初始细胞来源CD8⁺ CAR-T 细胞功能的靶点。过表达RUNX2可增强小鼠CAR-T 细胞的抗肿瘤疗效,该作用取决于既往细胞状态;同时也能增强人CAR-T 细胞功能。我们的数据表明,CAR-T 细胞既往抗原经历会决定其功能特征以及对转录因子介导功能增强的响应能力。

展开英文摘要原文

Although chimeric antigen receptor (CAR) T cells are effective against B-lineage malignancies, post-CAR relapse is common, and efficacy in other tumors is limited. These challenges may be addressed through rational manipulations to control CAR T cell function.

Here we examine the impact of cognate T cell antigen experience on subsequent CD8 + CAR T cell activity. Prior antigen encounter resulted in superior effector function against leukemia expressing low target antigen density at the expense of reduced proliferative capacity and susceptibility to dysfunction at limiting CAR doses.

Distinctive temporal transcriptomic and epigenetic profiles in naive-derived and memory-derived CAR T cells identified RUNX family transcription factors as potential targets to augment the function of naive-derived CD8 + CAR T cells. RUNX2 overexpression enhanced antitumor efficacy of mouse CAR T cells, dependent on prior cell state, and heightened human CAR T cell functions.

Our data demonstrate that prior antigen experience of CAR T cells determines functional attributes and amenability to transcription factor-mediated functional enhancement.

论文信息

作者
DeGolier KR、Danis E、D'Antonio M、Cimons J、Yarnell M、Kedl RM、Kohler ME、Scott-Browne JP
第一作者单位
Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.United States
通讯作者单位
Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. terry.fry@cuanschutz.edu.United States
文献类型
美国政府(非公共卫生署)资助研究 · 美国 NIH 资助研究
期刊
Nature immunology2025 Jan
原文标识
PubMed 39747430 · DOI 10.1038/s41590-024-02034-1